Clinical trials
Phase 2 Arthritis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
95 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 3 |
| 2006 | 7 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 4 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 3 |
| 2016 | 4 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 8 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 60 |
| Terminated | 15 |
| Withdrawn | 6 |
| Recruiting | 6 |
| Unknown status | 5 |
| Not yet recruiting | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Center for Research Resources (NCRR) | 5 |
| AbbVie | 4 |
| Novartis Pharmaceuticals | 4 |
| Aclaris Therapeutics, Inc. | 3 |
| Eli Lilly and Company | 3 |
| Pfizer | 3 |
| University of Leeds | 3 |
| ZetrOZ, Inc. | 3 |
| AHS Cancer Control Alberta | 2 |
| Amgen | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Arthritis | 95 |
| Arthritis, Rheumatoid | 32 |
| Joint Diseases | 22 |
| Osteoarthritis | 19 |
| Musculoskeletal Diseases | 16 |
| Connective Tissue Diseases | 13 |
| Osteoarthritis, Knee | 10 |
| Rheumatic Diseases | 10 |
| Rare Diseases | 9 |
| Arthralgia | 8 |
Trials
Showing 51 to 75 of 95. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.